Advanced Biomed Inc. released its financial results for the half-year period ended December 31, 2025. The company reported other income, net of USD 0.2 million for the six-month period, compared to an other expense, net of USD 0.07 million for the same period in the previous year. The increase in other income was primarily attributable to an exchange gain resulting from the revaluation of foreign currency balances. During the reporting period, Advanced Biomed Inc. completed the sale of 100 percent of the issued and outstanding shares of its wholly owned subsidiary, Advanced Biomed (HK) Limited, a Hong Kong company. As a result, the subsidiary was deconsolidated from the company's financial statements as of December 31, 2025. Additionally, the company made capital contributions to Advanced Biomed Taiwan to support research and development activities, including a contribution of USD 0.5 million in March 2025. No dividends or other distributions were made to stockholders during the period. The company noted that future dividends are subject to its ability to service debts and regulatory considerations related to cash transfers between subsidiaries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advanced Biomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-016458), on February 13, 2026, and is solely responsible for the information contained therein.
Comments